Dr Lal PathLabs: FY26 closes with the strongest quarterly growth in four years

Dr Lal PathLabs ended FY26 with a sharp pickup in momentum. Q4 FY26 revenue rose 16.6% year on year to INR 703 crore, which the company called its highest quarterly growth in the last 16 quarters. For the full year, revenue increased 12.2% to INR 2,763 crore.

The company attributed the growth largely to volumes. Sample volumes in Q4 rose 12.9% to 23.6 million, and full-year samples increased 10.4% to 94.5 million. Patient volumes also grew, but at a slower pace, implying that mix and tests per patient continued to play a role.

Volume-led growth, with realization tailwinds

Management highlighted that revenue per patient improved in Q4 to INR 956 from INR 887 last year, driven by an improvement in test mix and geographic mix. Tests per patient also increased to 3.21 from 3.07.

Preventive health packages remained a meaningful part of the business. SwasthFit contribution rose to 28% of Q4 revenue from 26% last year and to 27% for FY26 from 24% in FY25. On the call, management reiterated that preventive packages are a key lever for B2C growth.

Note: FY26 normalized numbers exclude INR 30 crore one-time cost related to Labour Codes; FY25 includes a one-time tax benefit from Suburban Diagnostics liquidation.

Margins: stable intent, but reinvestment continues

While growth accelerated, reported margins softened versus last year. Q4 EBITDA margin was 26.6% versus 28.1% in Q4 FY25. For FY26, reported EBITDA margin was 27.2% versus 28.3% in FY25.

Management repeatedly framed the margin movement as the outcome of deliberate reinvestment rather than a structural issue. The CFO cited higher spending on infrastructure upgrades and advertising and promotion as the key contributors to higher other expenses in Q4. For FY27, the company guided to maintain EBITDA margins in the 27% to 28% range, explicitly indicating that investments in labs and market expansion will continue.

One accounting nuance also mattered. The company highlighted exceptional items across the two years: a one-time INR 30 crore cost related to Labour Codes was booked in Q3 FY26, while FY25 carried a one-time INR 41 crore benefit linked to voluntary liquidation of Suburban Diagnostics. The company therefore asked investors to focus on normalized profitability, where FY26 normalized EBITDA was INR 783 crore and normalized PAT was INR 532 crore.

Expansion in access points and deepening in Tier 3 markets

The operating narrative remained centered on expanding reach. The company ended FY26 with 312 labs, 7,727 patient service centers and 13,935 pick-up points. Over the last two years, it added 32 labs, more than 1,900 patient service centers and 2,300 pick-up points.

A key theme was the rise of emerging markets within India. Revenue from Tier 3 plus locations increased to INR 1,090 crore in FY26 from INR 685 crore in FY23, taking Tier 3 plus share to 39% of total revenue. Management clarified on the call that Tier 3 expansion has not been realization-dilutive because pricing is run in clusters, and preventive packages can carry higher revenue per patient.

The company also shared its geography mix for FY26: Delhi NCR at 31%, Uttar Pradesh and Uttarakhand at 19%, Rest of North at 13%, East India at 15%, West India at 14%, South India at 6% and Others at 2%.

Scientific leadership and new bets

FY26 also featured a push to strengthen the scientific and specialty testing franchise. The company hosted Medllumina 2026, described as its first international medical conference, bringing together over 500 clinicians and thought leaders. Management positioned it as a platform to accelerate adoption of high-complexity testing in areas such as oncogenomics and transplant immunology.

Another visible move was the launch of Sovaaka, positioned as an AI-powered precision health screening concept in the premium wellness segment. Management clarified that only one centre has been launched so far and there is no plan to add additional Sovaaka centres in FY27. The focus for the next year is to build and stabilize the existing centre before scaling.

The company also announced incorporation of a wholly owned subsidiary in Dubai, UAE, to support international expansion over time. Management described international build-out as a 3 to 5 year journey, with the Dubai entity potentially serving as a base for exploring acquisitions, tie-ups or joint ventures in the region.

Alongside this, Dr Lal PathLabs announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited, a Mumbai-based diagnostics business with FY26 turnover of INR 6.11 crore. Management said the acquisition strengthens presence in a Mumbai micro-market where the company did not have a meaningful footprint.

Balance sheet strength and shareholder payouts

Management emphasized its strong liquidity position. Cash and cash equivalents in the presentation were shown at INR 1,526 crore for FY26. The company also stated that working capital was negative by 26 days.

On capital returns, the board recommended a final dividend of INR 4 per share for FY26. Management said total dividend for the year was INR 20.5 per share, described as 280% after adjustment for the 1:1 bonus issue completed in Q3 FY26.

What management guided for FY27

The company entered FY27 with explicit guidance on growth, profitability and capex.

Management guided for early to mid-teens revenue growth in FY27, and later clarified that the intent is roughly in the 13% to 15% range. EBITDA margin guidance was maintained at 27% to 28%, with management indicating that any upside would likely be reinvested into growth.

Capex guidance for FY27 was INR 100 crore to INR 120 crore, including maintenance capex, opening 12 to 15 labs, 1 to 2 radiology centres and investment in a precision diagnostics lab.

Takeaways

FY26 was a year where Dr Lal PathLabs combined steady execution with a stronger close, anchored by volume growth and a higher contribution from preventive packages. The company is clearly choosing to reinvest rather than optimize for short-term margin expansion, while still protecting profitability in a high-20s EBITDA band.

The FY27 guidance is important because it signals confidence that the last two years of network build-out, the recovery trajectory in the West and sustained growth in Delhi NCR can collectively lift growth into the early to mid-teens. At the same time, management kept expectations measured on newer bets like radiology and Sovaaka, suggesting a calibrated approach to scaling beyond core diagnostics.